Carbon Biosciences is a technology company.
Carbon Biosciences has raised $38.0M across 1 funding round.
Carbon Biosciences has raised $38.0M in total across 1 funding round.
Carbon Biosciences has raised $38.0M in total across 1 funding round.
Carbon Biosciences's investors include Agent Capital.
Carbon Biosciences is a biotechnology company developing genetic medicines for severe diseases using a proprietary parvovirus-based vector platform called PAVE (Parvovirus Augmented Vector Evolution).[1][2][4] It creates novel viral vectors with advantages like tissue specificity (e.g., lung and cardiac targeting), larger payloads (up to 5.9 kb, exceeding AAV vectors), liver detargeting, immune evasion for re-administration, and minimal neutralizing immunity, addressing key limitations in current gene therapies.[1][2][3][4] The company serves patients with genetic diseases such as cystic fibrosis (CF), with its lead candidate CGT-001 delivering the full-length CFTR gene to lung tissue in preclinical models.[2][4] Founded in 2021 and headquartered in Lexington, Massachusetts, Carbon launched from stealth in 2022 with $38 million in Series A funding from investors including the Cystic Fibrosis Foundation and Longwood Fund, fueling pipeline advancement in pulmonary and cardiac indications.[1][2][4]
Carbon Biosciences was founded in 2021, emerging from groundbreaking research by scientific co-founders John Engelhardt, director of the University of Iowa's Center for Gene Therapy, and Robert Kotin, professor at University of Massachusetts Chan Medical School.[2] The idea stemmed from leveraging natural viral evolution—specifically parvoviruses evolved over millions of years—combined with modern gene therapy advances to create superior delivery vectors via the PAVE platform.[1][2][4] Early traction came with the 2022 stealth exit and $38 million Series A, co-funded under a Cystic Fibrosis Foundation-Longwood collaboration, validating CGT-001's potential in CF models showing upper airway tropism and repeatable dosing.[2][4] Leadership includes President and CEO Joel Schneider, who emphasizes expanding gene therapy's role beyond current immunological and targeting hurdles.[2]
Carbon stands out in gene therapy through its non-AAV parvovirus vectors, engineered via PAVE for breakthroughs in delivery challenges:
Carbon rides the gene therapy boom, where market forces like rising genetic disease prevalence (e.g., CF affecting ~70,000 worldwide) and advances in viral vector tech drive a projected $20+ billion market by 2030, but face hurdles like AAV limitations in payload, immunity, and targeting.[2] Its timing capitalizes on post-2020 manufacturing leaps and parvovirus research, enabling first-in-class vectors for hard-to-treat tissues like lungs and heart—key for unmet needs in CF, heart failure, and beyond.[1][2][4] By partnering with AI firms like WhiteLab Genomics, Carbon influences the ecosystem, accelerating in silico design to cut costs/risks and expand genomic medicine to non-liver targets, potentially reshaping delivery standards.[4]
Carbon's near-term catalysts include advancing CGT-001 toward IND filing via optimized manufacturing and preclinical data, alongside pipeline expansion in cardiac/pulmonary indications using CBN vectors.[3][4] AI integrations and collaborations will likely yield novel candidates, while trends like redosable therapies and larger payloads position it to capture share in a competitive field dominated by AAV players. Its influence may grow through licensing or big pharma deals, evolving gene therapy from niche to mainstream for devastating diseases—ultimating the promise of viral evolution to transform patient outcomes.[1][2][4]
Carbon Biosciences has raised $38.0M across 1 funding round. Most recently, it raised $38.0M Series A in June 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2022 | $38.0M Series A | Agent Capital |